Today, biospecimen collections are used by multiple research groups for varying research aims, from basic research through clinical trials. A well-managed biobank is a critical prerequisite for high-quality biological research. The proper collection, processing, storage and tracking of biospecimens are critical components allowing researchers to better link molecular and clinical information. Thus, by necessity, biobanking is both a science and a business. Cambridge Healthtech Institute’s Fifth Annual Leaders in Biobanking: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge research.
Keynote Presentations:
- Andrew M. Dahlem, Ph.D., Eli Lilly and Company
- Norma J. Nowak, Ph.D., Empire Genomics LLC
- Anantha Shekhar, M.D., Ph.D., Indiana University School of Medicine
- Traci Runge, Breast Cancer Survivor and Stem Cell Therapy Recipient
Pre-Conference Events:
Post-Conference Event:
Podcasts: